Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.51 |
| ▸ | DHFR | P00374 | 5/20 | 0.41 |
| ▸ | TYMS | P04818 | 4/20 | 0.41 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.41 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.41 |
| ▸ | GART | P22102 | 1/20 | 0.41 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.41 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | CHIT1 | Q13231 | 1/20 | 0.32 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18780148 | 0.82 | TYMS (0.39) | PNPDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL207072 | 0.81 | TYMS (0.49) | DHFRTYMSFOLR2FOLR1GART | |
| SCHEMBL24845716 | 0.81 | PNP (0.57) | PNPDHFRTYMSFOLR2FOLR1 | |
| Water SCHEMBL20450131 | 0.81 | TYMS (0.39) | PNPDHFRTYMSFOLR2FOLR1 | |
| SCHEMBL1238667 | 0.80 | TYMS (0.46) | DHFRTYMSFOLR2FOLR1GART | |
| SCHEMBL20037503 | 0.76 | GART (0.56) | DHFRTYMSFOLR2FOLR1GART | |
| SCHEMBL20202023 | 0.76 | BACE1 (0.36) | PNPTYMSBACE1 | |
| SCHEMBL17776089 | 0.74 | GART (0.66) | DHFRTYMSFOLR2FOLR1GART | |
| SCHEMBL22104583 | 0.74 | GART (0.64) | DHFRTYMSFOLR2FOLR1GART | |
| SCHEMBL19268517 | 0.74 | GART (0.67) | DHFRTYMSFOLR2FOLR1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226214-A1 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, FCGR3B, FCGR2A | PNP 979/4885DHFR 2599/4885TYMS 1616/4885 |
| US-20230279426-A1 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | HAVCR2, ASGR1, FCGR3B | PNP 1279/4885DHFR 4085/4885TYMS 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.